

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lin, *et al.*

Group Art Unit: 1818

Serial No.: 08/182,183

Examiner: Marianne P. Allen

Filed: May 23, 1994

Docket No.: SYNE-225-E
(SYNE225/C4-US)For: GLIAL CELL LINE-
DERIVED NEUROTROPHIC
FACTOR

Date: September 11, 1997

DECLARATION REGARDING MATERIAL INCORPORATED BY REFERENCE
(M.P.E.P. 608.01(p))Assistant Commissioner of Patents
Washington, D. C. 20231

Sir:

Declarant

I am the Attorney for Applicant of this application.

Statement

The following amendatory material to the disclosure consists of the same material as that which was incorporated by reference in this application. The material is from Dayhoff, Atlas of Protein Sequence and Structure, Vol. 5, p. 124, column 2, lines 15-27, (1972), National Biochemical Research Foundation, Washington, D.C. which was incorporated by reference in the present application at page 20, line 21.

On page 20, line 22 after "reference.", please insert:


--In particular, Dayhoff describes that "[i]n practice, two related proteins may be aligned with the insertion of an average of 3 or 4 gaps in a length of 100

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

September 11, 1997


Date



residues. About 20% of the aligned amino acids are identical. Under these conditions, the statistical conclusion of common ancestry can be drawn with great confidence. Common ancestry may exist even though it cannot be proved from the comparison of two sequences. The use of additional evidence, such as the correspondence of the active sites, the comparisons of many related sequences with one new one, and the nature of the three-dimensional structures, will eventually permit the inference of relationships of even more remotely related structures."--

I further declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both (18 U.S.C. 1001), and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Daniel R. Curry
Attorney for Applicant
Registration No: 32,727
Phone: (805) 447-8102
Date: September 11, 1997

Please send all future correspondence to:

U.S. Patent Operations/DRC
M/S 10-1-B
AMGEN INC.
Amgen Center
1840 Dehavilland Drive
Thousand Oaks, California 91320-1789